OncoMatch

OncoMatch/Clinical Trials/NCT06939127

Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB NSCLC

Is NCT06939127 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Neoadjuvant Cryoablation Combined with Tislelizumab and Chemotherapy and Adjuvant tislelizumab for nsclc (non-small cell lung cancer).

Phase 2RecruitingTianjin Medical University Cancer Institute and HospitalNCT06939127Data as of May 2026

Treatment: Neoadjuvant Cryoablation Combined with Tislelizumab and Chemotherapy · Adjuvant tislelizumabThis is a Phase II single-arm study designed to evaluate the efficacy and safety of cryoablation combined with tislelizumab and platinum-based doublet chemotherapy as neoadjuvant therapy, followed by adjuvant tislelizumab therapy in patients with resectable stage II-IIIB non-small cell lung cancer (NSCLC). The study consists of a screening phase, a treatment phase (including the neoadjuvant stage, surgery, and adjuvant stage), a safety follow-up period, and a survival follow-up period.

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Small Cell Lung Carcinoma

Biomarker criteria

Excluded: EGFR mutation

Known EGFR mutations [excluded]. For non-squamous NSCLC, EGFR mutation status must be confirmed locally or centrally if unknown.

Excluded: ALK fusion

Known...ALK translocations [excluded].

Disease stage

Required: Stage II, IIIA, IIIB (AJCC 9th edition)

Excluded: Stage IV, IIIC

Histologically confirmed stage II-IIIB NSCLC (AJCC 9th edition). Locally advanced, unresectable disease, regardless of stage or metastasis (stage IV) [excluded]. Patients with mediastinal lymph node involvement on CT must undergo sampling for clinical staging to exclude stage IIIB/C.

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)
Max 0 prior lines

Cannot have received: chemotherapy

Cannot have received: radiation therapy

Lab requirements

Cardiac function

adequate cardiopulmonary function for radical surgical resection

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify